PT1017721E - Moléculas de mhc recombinantes úteis para manipulação de células t específicas do antigénio - Google Patents

Moléculas de mhc recombinantes úteis para manipulação de células t específicas do antigénio Download PDF

Info

Publication number
PT1017721E
PT1017721E PT98946814T PT98946814T PT1017721E PT 1017721 E PT1017721 E PT 1017721E PT 98946814 T PT98946814 T PT 98946814T PT 98946814 T PT98946814 T PT 98946814T PT 1017721 E PT1017721 E PT 1017721E
Authority
PT
Portugal
Prior art keywords
cells
specific
antigen
polypeptides
manipulation
Prior art date
Application number
PT98946814T
Other languages
English (en)
Inventor
Gregory G Burrows
Arthur A Vanderbark
Original Assignee
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science filed Critical Univ Oregon Health & Science
Publication of PT1017721E publication Critical patent/PT1017721E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT98946814T 1997-09-16 1998-09-15 Moléculas de mhc recombinantes úteis para manipulação de células t específicas do antigénio PT1017721E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6455297P 1997-09-16 1997-09-16
US6455597P 1997-10-10 1997-10-10

Publications (1)

Publication Number Publication Date
PT1017721E true PT1017721E (pt) 2009-05-07

Family

ID=26744627

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98946814T PT1017721E (pt) 1997-09-16 1998-09-15 Moléculas de mhc recombinantes úteis para manipulação de células t específicas do antigénio

Country Status (12)

Country Link
US (4) US6270772B1 (pt)
EP (1) EP1017721B1 (pt)
JP (1) JP4485679B2 (pt)
AT (1) ATE423789T1 (pt)
AU (1) AU741130B2 (pt)
CA (1) CA2302779C (pt)
CY (1) CY1110274T1 (pt)
DE (1) DE69840600D1 (pt)
DK (1) DK1017721T3 (pt)
ES (1) ES2323098T3 (pt)
PT (1) PT1017721E (pt)
WO (1) WO1999014236A1 (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE423789T1 (de) * 1997-09-16 2009-03-15 Univ Oregon Health & Science Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t- zellen
US20030007978A1 (en) * 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
ES2261197T3 (es) * 1999-04-16 2006-11-16 Ortho-Mcneil Pharmaceutical, Inc. Metodo para la deteccion de celulas t especificas de antigeno.
PT1517913E (pt) * 1999-10-07 2007-05-31 Corixa Corp Sequência codificante de mycobacterium turberculosis para expressão de proteínas heterólogas.
US7009042B1 (en) * 1999-10-07 2006-03-07 Corixa Corporation Methods of using a Mycobacterium tuberculosis coding sequence to facilitate stable and high yield expression of the heterologous proteins
US8088586B2 (en) * 2000-03-17 2012-01-03 Oxford Radcliffe Hospital Nhs Trust Method of producing a body fluid sample depleted of anti-MHC antibodies
US8609436B2 (en) * 2000-03-17 2013-12-17 Guy's & St Thomas' Hospital NHS Trust (“GST”) Method
WO2001070245A1 (en) * 2000-03-22 2001-09-27 Corixa Corporation Immune mediators and related methods
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
JP4608184B2 (ja) * 2001-03-14 2011-01-05 ダコ デンマーク アクティーゼルスカブ 新規なｍｈｃ分子構築物、ならびに診断および処置のためにこれらの構築物を用いる方法、ならびにｍｈｃ分子の使用
US8022190B2 (en) 2001-06-19 2011-09-20 Technion Research & Development Foundation Ltd. Immuno-molecules containing viral proteins, compositions thereof and methods of using
US20030144477A1 (en) * 2001-10-04 2003-07-31 Corixa Corporation Immunodominant acetylcholine receptor alpha subunit peptide: MHC complexes
US20030199024A1 (en) * 2002-04-19 2003-10-23 Hansen Ted H. Single chain trimers of class I MHC molecules
US20040072262A1 (en) * 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
US20040248205A1 (en) * 2003-04-16 2004-12-09 Stern Lawrence J. Major histocompatibility complex (MHC)-peptide arrays
US20040225112A1 (en) * 2003-05-06 2004-11-11 Crew Mark D. Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity
JP2006524991A (ja) * 2003-05-08 2006-11-09 エクサイト セラピーズ インコーポレーティッド 抗原特異的ｔ細胞の作製および単離の方法
US9063145B2 (en) 2003-07-23 2015-06-23 Cellular Technology Limited Multivalent opsonophagocytic assay using bead array and imaging
US7598093B2 (en) * 2003-07-23 2009-10-06 Ctl Analyzers, Llc Nanoparticle and microparticle based detection of cellular products
ES2559409T3 (es) 2003-09-05 2016-02-12 Oregon Health & Science University Moléculas de MHC recombinantes monoméricas útiles para la manipulación de células T específicas de antígenos
WO2005047902A1 (en) * 2003-11-03 2005-05-26 Beckman Coulter, Inc. Solution-based methods for detecting mhc-binding peptides
CA2550258A1 (en) 2003-12-23 2005-07-07 Santaris Pharma A/S Oligomeric compounds for the modulation of bcl-2
WO2005111624A2 (en) * 2004-05-07 2005-11-24 Beckman Coulter, Inc. Mhc bridging system for detecting ctl-mediated lysis of antigen presenting cells
EP2226332A1 (en) * 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
EP1877440A4 (en) * 2005-03-18 2009-07-29 Univ Oregon Health & Science RECOMBINANT MHC MOLECULES FOR USE IN THE MANIPULATION OF ANTIGEN-SPECIFIC T CELLS
AU2006269490B8 (en) * 2005-07-06 2011-09-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Stable quantitation and detection of immune response levels with non-zero background peptides
US8518697B2 (en) * 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
KR101442209B1 (ko) 2006-05-19 2014-11-18 테크니온 리서치 엔드 디벨로프먼트 화운데이션 엘티디. 융합 단백질, 이의 용도 및 이의 제조방법
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
US7719317B2 (en) * 2006-12-01 2010-05-18 The Regents Of The University Of Michigan Clock distribution network architecture with resonant clock gating
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP3620465A1 (en) 2007-07-03 2020-03-11 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US8406860B2 (en) 2008-01-25 2013-03-26 Novadaq Technologies Inc. Method for evaluating blush in myocardial tissue
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US8491913B2 (en) 2009-03-07 2013-07-23 Oregon Health & Science University Compositions and methods using recombinant MHC molecules for the treatment of stroke
US20110008382A1 (en) * 2009-03-07 2011-01-13 Burrows Gregory G Compositions and methods using recombinant MHC molecules for the treatment of uveitis
CA2757287C (en) 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
EP3311833A3 (en) * 2009-08-26 2018-07-25 Selecta Biosciences, Inc. Compositions that induce t cell help
GB201002730D0 (en) 2010-02-18 2010-04-07 Uni I Oslo Product
JP2013535963A (ja) * 2010-07-15 2013-09-19 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド Ｍｈｃクラスｉｉと糖尿病関連自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体
WO2012007951A1 (en) * 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
EP2611827A4 (en) * 2010-09-03 2014-03-19 Univ Oregon Health & Science RECEPTOR LIGANDS OF RECOMBINANT T LYMPHOCYTES WITH COVALENCE-RELATED PEPTIDES
MX362653B (es) * 2010-09-29 2019-01-30 Uti Lp Composiciones de alta densidad de partícula que comprenden complejos de nanoesferas bioabsorbibles biocompatibles y sus usos.
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US8685404B2 (en) 2011-01-31 2014-04-01 Oregon Health & Science University Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
US9260506B2 (en) * 2011-04-07 2016-02-16 Oregon Health & Science University Treatment of retinal disorders with recombinant T cell receptor ligand (RTL)
EP2511659A1 (de) 2011-04-14 2012-10-17 Hexagon Technology Center GmbH Geodätisches Markierungssystem zur Markierung von Zielpunkten
EP2704693A4 (en) 2011-04-29 2015-01-28 Selecta Biosciences Inc TAXED RELEASE OF IMMUNOSUPPRESSIVA FROM SYNTHETIC NANOTORIES
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
ES2914374T3 (es) 2011-10-28 2022-06-10 Regeneron Pharma Ratones modificados genéticamente que expresan moléculas quiméricas del complejo de histocompatibilidad mayor (MHC) de clase II
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
HUE035652T2 (en) 2011-10-28 2018-05-28 Regeneron Pharma Genetically Modified Major Histocompatibility Complex Mice
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
MX2014008146A (es) * 2012-01-06 2016-02-03 Univ Oregon Health & Science Constructos de mhc parciales y metodos de uso.
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
CN111484999A (zh) 2013-02-20 2020-08-04 瑞泽恩制药公司 人源化的t细胞共受体的小鼠
CA2900824A1 (en) 2013-02-22 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
ES2730273T3 (es) 2013-11-04 2019-11-11 Uti Lp Métodos y composiciones para inmunoterapia sostenida
WO2016014725A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
HRP20231039T1 (hr) 2015-04-06 2023-12-22 Regeneron Pharmaceuticals, Inc. Imunosni odgovori posredovani humaniziranim t stanicama kod ne-humanih životinja
WO2016198932A2 (en) 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
US20170196957A1 (en) * 2016-01-08 2017-07-13 Oregon Health & Science University Recombinant t cell receptor ligand compositions and methods for treatment of prostate cancer
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
CN111032850A (zh) 2017-04-27 2020-04-17 朱诺治疗学有限公司 寡聚粒子试剂及其使用方法
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
KR20230086765A (ko) 2020-10-13 2023-06-15 얀센 바이오테크 인코포레이티드 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260422A (en) 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5468481A (en) 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US6106840A (en) * 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5130297A (en) 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US6011146A (en) * 1991-11-15 2000-01-04 Institut Pasteur Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
US5734023A (en) 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US5583031A (en) 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
EP0997477B1 (en) * 1994-07-29 2006-03-15 Sunol Molecular Corporation MHC complexes and uses thereof
US7074904B2 (en) * 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
US5595881A (en) * 1994-08-09 1997-01-21 Anergen, Inc. Method for the detection of antigen presenting cells
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
ATE423789T1 (de) * 1997-09-16 2009-03-15 Univ Oregon Health & Science Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t- zellen
US6232445B1 (en) * 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof

Also Published As

Publication number Publication date
US20080064859A1 (en) 2008-03-13
US6815171B2 (en) 2004-11-09
JP2001516571A (ja) 2001-10-02
ES2323098T3 (es) 2009-07-06
JP4485679B2 (ja) 2010-06-23
US20050074853A1 (en) 2005-04-07
ATE423789T1 (de) 2009-03-15
CA2302779C (en) 2010-02-02
EP1017721B1 (en) 2009-02-25
US6270772B1 (en) 2001-08-07
CA2302779A1 (en) 1999-03-25
EP1017721A4 (en) 2003-04-09
AU741130B2 (en) 2001-11-22
DE69840600D1 (de) 2009-04-09
CY1110274T1 (el) 2015-01-14
AU9375098A (en) 1999-04-05
US7265218B2 (en) 2007-09-04
DK1017721T3 (da) 2009-04-20
US20020176864A1 (en) 2002-11-28
WO1999014236A1 (en) 1999-03-25
EP1017721A1 (en) 2000-07-12

Similar Documents

Publication Publication Date Title
PT1017721E (pt) Moléculas de mhc recombinantes úteis para manipulação de células t específicas do antigénio
WO2006102170A3 (en) Recombinant mhc molecules useful for manipulation of antigen-specific t cells
ATE383430T1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
BR9913331A (pt) Expressão e exportação de inibidores de angiogênese como imunofusinas
ATE257160T1 (de) Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde
MY122568A (en) Resin for a mineral wool binder comprising the reaction product of an amine with a first and second anhydride
IN178499B (pt)
DE68926675D1 (de) Von mhc gestützte konjugate zur verwendung bei der steigerung der autoimmunität
DK1157042T3 (da) Fremstilling af tetravalente antistoffer
DE69632625D1 (de) Mykrobakterielle proteine, mikroorganismen welche diese produzieren und ihre verwendung als impfstoff und zum nachweis von zuberkulose
DK1616575T3 (da) Fremgangsmåde til behandling af inflammation
DE69532674D1 (de) Nicht-antigene von aminen abgeleitete polymere und polymerkonjugate
EP0815125A4 (en) gC1q RECEPTOR, BINDING HIV-1 gp120 REGION, RELATED PEPTIDES AND ANTIBODIES
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
NO20100685L (no) Polypeptid samt anvendelse derav og peptidkompleks, og fremgangsmate for identifisering av et organisk eller uorganisk molekyl
IL138424A (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
DE69434384D1 (de) Metalkomplexbildner
AU8040898A (en) Type-1 ribosome-inactivating protein
DE69736838D1 (de) Herpesvirus saimiri als viraler vektor
NO981748L (no) Nytt DNA, samt en fremgangsmÕte for fremstilling av protein ved anvendelse av dette
DE69028094D1 (de) Konjugate von antikörpern mit variablen domänen
FI970735A0 (fi) Menetelmät autoimmuunisairauksien käsittelyyn käyttökelpoisten yhdisteiden identifioimiseksi
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
WO2003084995A3 (en) Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
DE69631624D1 (de) Antikörper gegen menschliches restrictin